Obeticholic Acid interactions

Conditions

Conditions in which Obeticholic Acid needs care, as documented in this source.

• Cholestasis

  Major

  Obeticholic acid is contraindicated in patients with complete biliary obstruction.

  1 source

  1. "Product Information. Ocaliva (obeticholic acid)." Intercept Pharmaceuticals, Inc. (2016):

• Liver Failure

  Major

  In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with primary biliary cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when obeticholic acid was dosed more frequently than recommended. The recommended starting dosage is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior hepatic decompensation event. Patients in treatment should be closely monitored for progression of PBC disease, including liver- related complications, with laboratory and clinical assessments. Dosage adjustment, interruption or discontinuation may be required.

  1 source

  1. "Product Information. Ocaliva (obeticholic acid)." Intercept Pharmaceuticals, Inc. (2016):

• Hyperlipidemias

  Moderate

  Patients with primary biliary cholangitis generally exhibit hyperlipidemia characterized by a significant elevation in total cholesterol primarily due to increased levels of high-density lipoprotein-cholesterol (HDL-C). Exercise care when using obeticholic acid in patients with lipids disorder. It is recommended to monitor patients for changes in serum lipid levels during treatment with obeticholic acid. For patients who do not respond to treatment after 1 year at the highest recommended dosage that can be tolerated (maximum of 10 mg once daily), and who experience a reduction in HDL-C, weigh the potential risks against the benefits of continuing treatment.

  1 source

  1. "Product Information. Ocaliva (obeticholic acid)." Intercept Pharmaceuticals, Inc. (2016):